Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMR5GSB)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
3,4,5,6-Tetrahydrouridine; NSC-112907; NSC 112907; CHEMBL2311128; 18771-50-1; U 23284; NSC-112907-D; BRN 0752319; 2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-; NSC112907; AC1L1H1G; SCHEMBL587704; 3,4,5, 6-Tetrahydrouridine; 2(1H)-Pyrimidinone, tetrahydro-4-hydroxy-1-.beta.-D-ribofuranosyl-; UCKYOOZPSJFJIZ-XVKVHKPRSA-N; MolPort-044-561-340; BDBM50421666; AKOS032953792; DB12484; LS-7719; CS-7633; HY-15345; 3,4,5,6-Tetrahydrouridine (> 80% by HPLC); J-012078
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Normal (Transformed)
Lung
Lung adenocarcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
Umbilical vein
Normal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
